SCHEMBL5738558

SCHEMBL5738558

COc1ccc(/C(=C(\CCCl)c2ccc(Cl)cc2)c2ccc(OCCN(C)C)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.74
LMNA P02545 2/20 0.74
ESRRG P62508 13/20 0.68
ESR1 P03372 10/20 0.68
ESR2 Q92731 3/20 0.58
MAPT P10636 3/20 0.54
MEN1 O00255 2/20 0.54
TP53 P04637 2/20 0.54
CYP3A4 P08684 2/20 0.54
ESRRA P11474 2/20 0.54
KMT2A Q03164 2/20 0.54
NPC1 O15118 1/20 0.54
NR1I2 O75469 1/20 0.54
PRKD3 O94806 1/20 0.54
ABCB11 O95342 1/20 0.54
EGFR P00533 1/20 0.54
GBA1 P04062 1/20 0.54
NR3C1 P04150 1/20 0.54
ERBB2 P04626 1/20 0.54
PRKCG P05129 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5738332 1.00 HTR6 (0.74) HTR6LMNAESRRGESR1ESR2
SCHEMBL5738338 1.00 HTR6 (0.74) HTR6LMNAESRRGESR1ESR2
SCHEMBL5738249 0.95 HTR6 (0.81) HTR6LMNAESRRGESR1ESR2
SCHEMBL5738252 0.95 HTR6 (0.81) HTR6LMNAESRRGESR1ESR2
SCHEMBL5738255 0.95 HTR6 (0.81) HTR6LMNAESRRGESR1ESR2
SCHEMBL5738741 0.91 ESR1 (0.72) HTR6LMNAESRRGESR1ESR2
SCHEMBL5725510 0.91 ESR1 (0.72) HTR6LMNAESRRGESR1ESR2
SCHEMBL5736463 0.91 HTR6 (0.91) HTR6LMNAESRRGESR1ESR2
SCHEMBL5737155 0.91 HTR6 (0.91) HTR6LMNAESRRGESR1ESR2
SCHEMBL5736471 0.91 HTR6 (0.91) HTR6LMNAESRRGESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1705169-A2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators Hormos Medical Ltd. (FI) 2006-09-27 EP claimed
US-6875775-B2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD (FI) 2005-04-05 US claimed
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD. 2003-12-04 US claimed
EP-1235776-A1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS Hormos Medical Corporation (FI) 2002-09-04 EP claimed
WO-2001036360-A1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS HORMOS MEDICAL CORPORATION (FI) 2001-05-25 WO claimed
EP-1705169-A2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators Hormos Medical Ltd. (FI) 2006-09-27 EP disclosed
US-6875775-B2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD (FI) 2005-04-05 US disclosed
US-6576645-B1 Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect HORMOS MEDICAL OY LTD (FI) 2003-06-10 US disclosed
EP-1235776-A1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS Hormos Medical Corporation (FI) 2002-09-04 EP disclosed
WO-2001036360-A1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS HORMOS MEDICAL CORPORATION (FI) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators ESR2, ESR1, GPER1 HTR6 182/4885LMNA 4585/4885ESRRG 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.